The question sounds like it should have a simple answer, and for a long time it did: injections worked and pills did not. That is no longer true. There are now oral GLP-1s with double-digit weight-loss results in phase 3 trials, and one of them does not even require the awkward fasting ritual that made the first generation hard to live with. The honest comparison is narrower than “which is better” — it is about how much efficacy you trade for how much convenience, and the numbers for that trade are now public.
What the trials show, side by side
Every figure below is a mean percent change in body weight from a phase 3 trial against placebo. They are not head-to-head comparisons — different trials, different populations, different durations — so treat them as a range rather than a ranking. The pattern is still clear.
| Drug and route | Dose | Mean weight change | Trial |
|---|---|---|---|
| Tirzepatide — injection | 15 mg weekly | −20.9% at 72 weeks | SURMOUNT-1 |
| Oral semaglutide — tablet | 50 mg daily | −15.1% at 68 weeks | OASIS 1 |
| Semaglutide — injection | 2.4 mg weekly | −14.9% at 68 weeks | STEP 1 |
| Oral semaglutide — tablet | 25 mg daily | −13.6% at 64 weeks | OASIS 4 |
| Orforglipron — tablet | 36 mg daily | −11.2% at 72 weeks | ATTAIN-1 |
The single most useful line in that table is the middle one. Oral semaglutide at 50 mg produced −15.1% against −2.4% for placebo at week 68,[1] which sits alongside the −14.9% that injectable semaglutide 2.4 mg produced against −2.4% in STEP 1.[2] A pill matching an injection was the thing that was supposed to be impossible.
The catch is dose. The oral semaglutide dose that reached the US market for weight management is 25 mg, which produced −13.6% at week 64 against −2.2% for placebo — a good result, but no longer level with the injection.[3] Orforglipron, the first oral small-molecule agonist to be approved for weight management, produced −11.2% at 36 mg over 72 weeks, with 6 mg and 12 mg giving −7.5% and −8.4%.[4] And injectable tirzepatide sits well above all of them at −20.9%.[5]
The part nobody mentions until you are taking it
Semaglutide is a peptide, and peptides are destroyed by digestion. The tablet solves this with an absorption enhancer and a strict administration protocol, which the label spells out: take it on an empty stomach in the morning with water, no more than 4 ounces, and then wait at least 30 minutes before eating, drinking anything else, or taking any other oral medication.[6]
That is a daily commitment, every morning, indefinitely, and it interacts with every other pill someone takes at breakfast. Set against a weekly injection that can be given at any hour with food, the convenience argument for a peptide tablet is far weaker than “no needles” makes it sound. People who dislike injections should weigh a once-a-week needle against a 30-minute fast every single morning.
Side effects do not improve with the pill
A common assumption is that swallowing the drug is gentler than injecting it. The trials do not support that. In the OASIS 4 trial of oral semaglutide 25 mg, gastrointestinal adverse events occurred in 74.0% of the oral semaglutide group against 42.2% on placebo.[3] In the orforglipron obesity trial, adverse events led to discontinuation in 5.3% to 10.3% of participants across the dose groups against 2.7% on placebo, and the most common were gastrointestinal and mostly mild to moderate.[4]
That is the same profile, on the same timeline, as the injections — the mechanism is systemic, not local, so the route of entry does not change it. Our GLP-1 gastrointestinal side effects guide covers the shape of it, and constipation on a GLP-1 the effect that behaves least predictably.
How to actually choose
Three questions settle it more usefully than the pill-versus-needle framing. First, how much weight loss do you need — if the answer is the maximum available, the evidence still points to injectable tirzepatide, and no oral option is close. Second, can you hold the morning fasting window every day: if not, a peptide tablet is the wrong choice and orforglipron or an injection is the right one. Third, what is actually available to you at a price you can sustain, since the oral options have their own supply and coverage picture — see GLP-1 cost and insurance coverage and our comparison of providers prescribing oral GLP-1s.
Whichever route, the dose you settle on matters more than the format — see GLP-1 maintenance dosing — and so does what happens if you stop, which is unchanged by whether you were swallowing or injecting: what the withdrawal trials show. For the deeper background on each oral agent, see the Wegovy pill evidence, oral semaglutide in the PIONEER program and whether an oral tirzepatide exists.
The honest bottom line
A pill can now do what an injection does — oral semaglutide 50 mg matched injectable semaglutide 2.4 mg to within 0.2 of a percentage point — but not at the doses most people will actually be prescribed, and never at tirzepatide’s level. The gastrointestinal side effects come along regardless of route. And for peptide tablets the real cost is not efficacy but the daily fasting protocol, which is why the first small-molecule pill that escapes it matters more than its weight-loss number suggests.